Fresh analysis suggests that patients who discontinue new weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Findings released in a leading health publication shows that while obese people often shed substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users buying such medications must be aware of the risk of fast weight regain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to starting mass in about one and a half years.
Weighing Treatments
The analysis, which looked at 37 of trials involving thousands of patients, compared the results of these new drugs with older methods.
The team point out that people who lose weight through lifestyle changes alone usually experience a less rapid creep back—around 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Doctors suggest the way of the injections explains the heightened rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means appetite is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
Medical guidelines suggest the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the significant potential of weight regain, the therapy is often long-term.
This view is reinforced by drug manufacturers, who state that the results "highlight the persistent nature of excess weight," similar to managing diseases like hypertension.
Patient Testimonies
People who have discontinued the medication describe a intense resurgence of appetite.
"It felt as if something flipping and you're instantly extremely hungry," recalled a patient.
This challenge is worsened if individuals have not developed lasting dietary or behavioural modifications during therapy.
Growing Use
Recent estimates suggest that a significant number of people in the UK have used these injections in the past year, with desire being substantial.
- Use is greater among women than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated lifestyle support.
